What is AmideBio?
AmideBio specializes in the development of novel peptide drug candidates aimed at addressing metabolic diseases through its in-silico design and peptide synthesis capabilities. The company also offers custom synthesis services and maintains a catalog of high-purity peptides for clients seeking cost-effective solutions. Their focus is on tackling significant therapeutic challenges in the metabolic disease sector. AmideBio serves a diverse range of clients in the pharmaceutical and biotechnology industries, positioning itself as a key player in metabolic disease therapeutics.
How much funding has AmideBio raised?
AmideBio has raised a total of $3.5M across 2 funding rounds:
Private Equity
$763K
Grant
$2.7M
Private Equity (2017): $763K, investors not publicly disclosed
Grant (2022): $2.7M led by The National Institute of Diabetes and Digestive and Kidney Diseases
Key Investors in AmideBio
The National Institute of Diabetes and Digestive and Kidney Diseases
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a U.S. government agency focused on research related to diabetes, digestive, and kidney diseases, indicating a strong interest in metabolic health solutions.
What's next for AmideBio?
The recent major strategic investment indicates AmideBio is likely entering a scaling phase, potentially for clinical trials or broader market penetration of its peptide-based therapies. This enterprise-level funding will enable the company to accelerate its research and development pipeline, further solidify its market position in metabolic disease treatment, and expand its service offerings in custom peptide synthesis. The company's trajectory suggests a strong focus on innovation and strategic partnerships within the biotech sector.
See full AmideBio company page
